Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10005080 | 0.86 | CASP3 (0.55) | KDM4EPOLBTP53MAPTRAB9A | |
| SCHEMBL10005077 | 0.86 | MAPT (0.53) | KDM4EPOLBTP53USP2MAPT | |
| Hydrochloric Acid SCHEMBL10921109 | 0.83 | ALDH1A1 (0.55) | KDM4ETP53MAPTRAB9ANPC1 | |
| SCHEMBL9045395 | 0.83 | HSD17B10 (0.56) | HSD17B10KDM4EPOLBTP53USP2 | |
| SCHEMBL10005071 | 0.83 | MAPT (0.51) | HSD17B10KDM4EPOLBTP53USP2 | |
| SCHEMBL9042363 | 0.83 | RAB9A (0.63) | HSD17B10KDM4EPOLBTP53MAPT | |
| SCHEMBL29874275 | 0.81 | TP53 (0.76) | HSD17B10KDM4EPOLBTP53USP2 | |
| SCHEMBL3345659 | 0.80 | HSD17B10 (0.55) | HSD17B10KDM4EPOLBTP53USP2 | |
| SCHEMBL10004971 | 0.79 | HSD17B10 (0.54) | HSD17B10KDM4EPOLBTP53USP2 | |
| SCHEMBL10291489 | 0.75 | ALDH1A1 (0.51) | HSD17B10KDM4ETP53USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471944-B1 | Novel peptidase substrates | BIOMERIEUX SA (FR) | 2016-09-14 | — | — | EP | disclosed |
| EP-2155892-B1 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-1924357-B1 | CARBONYLATION METHOD BY ADDING SECONDARY STERICALLY HINDERED AMINES | EVONIK DEGUSSA GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8216800-B2 | Substrates for detecting peptidase activity and methods using the substrates | BIOMERIEUX (FR) | 2012-07-10 | — | — | US | disclosed |
| EP-2471944-A1 | Novel peptidase substrates | bioMérieux (FR) | 2012-07-04 | — | — | EP | disclosed |
| US-20100099128-A1 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2155892-A2 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008152306-A2 | NOVEL PEPTIDASE SUBSTRATES | bioMérieux (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099128-A1 | NOVEL PEPTIDASE SUBSTRATES | XPNPEP1, DPEP1, DDAH1 | HSD17B10 1530/4885KDM4E 2868/4885POLB 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.